ASCO-GI – Leap falters again
Randomised data will be needed to answer lingering questions about DKN-01.
Randomised data will be needed to answer lingering questions about DKN-01.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.